HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Find → Understand → Decide

Stranded asset discovery

Find leads where development or the surrounding company stopped. Discovery priority is separate from buyer qualification.

Bounded historical coverage · 0 HIGH / 111 MEDIUM / 956 LOW. No current availability or investment recommendation is implied. SEC retrieval is partial.

1067 exact-label leads · page 3

MEDIUM · POSSIBLE / INVESTIGATE

Balanced split dose of methadone

Why stranded (event context): financing failure

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · New label

MEDIUM · POSSIBLE / INVESTIGATE

bevacizumab

Why stranded (event context): efficacy failure; inadequate public evidence; recruitment/execution failure; strategic reprioritization

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

MEDIUM · POSSIBLE / INVESTIGATE

Camrelizumab

Why stranded (event context): supply failure

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · New label

MEDIUM · POSSIBLE / INVESTIGATE

Carboplatin

Why stranded (event context): efficacy failure; inadequate public evidence; recruitment/execution failure; strategic reprioritization

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

MEDIUM · POSSIBLE / INVESTIGATE

Cemiplimab

Why stranded (event context): financing failure; inadequate public evidence; trial-design failure

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

MEDIUM · POSSIBLE / INVESTIGATE

Cetuximab

Why stranded (event context): financing failure; inadequate public evidence; safety failure

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

MEDIUM · POSSIBLE / INVESTIGATE

Cetuximab Sarotalocan Sodium

Why stranded (event context): financing failure

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

MEDIUM · POSSIBLE / INVESTIGATE

Chemotherapy

Why stranded (event context): financing failure; inadequate public evidence; trial-design failure

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

MEDIUM · POSSIBLE / INVESTIGATE

Cisplatin

Why stranded (event context): efficacy failure; financing failure; inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

MEDIUM · POSSIBLE / INVESTIGATE

Clindamycin phosphate 6 mg/1ml for injection

Why stranded (event context): recruitment/execution failure

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · New label

MEDIUM · POSSIBLE / INVESTIGATE

Cyclophosphamide

Why stranded (event context): financing failure; inadequate public evidence; recruitment/execution failure

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

MEDIUM · POSSIBLE / INVESTIGATE

Dexmedetomidine

Why stranded (event context): financing failure; inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap